Discovery Life Sciences Appoints Cell & Gene Therapy CTO

Discovery Life Sciences, a specialist in biospecimen and biomarkers, has appointed Dominic Clarke, Ph.D. as Chief Technical Officer of Cell & Gene Therapy.  In this role, Dr. Clarke will work to further establish Discovery as a global leader in cell and gene therapy materials and analytical services to support the development and manufacture of advanced therapies.

"As a highly experienced and recognized leader in the cell and gene therapy industry, Dominic's addition to the Discovery team provides a significant enhancement to our already rapidly expanding Cell and Gene Therapy Services Division," said Glenn Bilawsky, Chief Executive Officer of Discovery.  "The cell and gene therapy industry acknowledges his proficiency in evaluating and implementing technological innovations on a global scale.  His knowledge, experience, and skillset will significantly accelerate our ability to advance researchers' cell therapy programs from early discovery through to manufacturing."

Dr. Clarke has more than 15 years of cell and gene related experience, and is the acting chair for the International Society for Cell and Gene Therapies (ISCT) Process and Product Development Committee – a global industry leadership forum for translating research and process development from bench to clinic through education and guidance.  Prior to joining the compny, he served as Global Head of Cell Therapy for HemaCare, a Charles River company, where he developed and led the company's global cell therapy corporate strategy, provided scientific and technical expertise both operationally and commercially, and spearheaded innovation across.